Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Four reported deaths prompt warning about Mifeprex
August 15th, 2005
The U.S. Food and Drug Administration (FDA) is investigating recently reported serious adverse events associated with mifepristone (trade name Mifeprex, also known as RU-486). As a result, the FDA is issuing a public health advisory highlighting the risk of sepsis or blood infection when undergoing medical abortion using Mifeprex and misoprostol in a manner that is not consistent with the approved labeling. There are now four cases of deaths from infection from September, 2003 to June, 2005, following medical abortion with these drugs. "The FDA is committed to sharing emerging drug information with the public and we believe it is important to share...
Source: Pharma Business Week (2005-08-15)
|
